Growth Metrics

Ani Pharmaceuticals (ANIP) Non-Current Debt (2017 - 2025)

Historic Non-Current Debt for Ani Pharmaceuticals (ANIP) over the last 9 years, with Q3 2025 value amounting to $297.7 million.

  • Ani Pharmaceuticals' Non-Current Debt fell 487.06% to $297.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $297.7 million, marking a year-over-year decrease of 487.06%. This contributed to the annual value of $309.1 million for FY2024, which is 852.79% up from last year.
  • Per Ani Pharmaceuticals' latest filing, its Non-Current Debt stood at $297.7 million for Q3 2025, which was down 487.06% from $301.5 million recorded in Q2 2025.
  • In the past 5 years, Ani Pharmaceuticals' Non-Current Debt registered a high of $312.9 million during Q3 2024, and its lowest value of $169.0 million during Q1 2021.
  • Moreover, its 5-year median value for Non-Current Debt was $285.7 million (2022), whereas its average is $274.3 million.
  • Per our database at Business Quant, Ani Pharmaceuticals' Non-Current Debt tumbled by 1015.93% in 2021 and then skyrocketed by 6942.75% in 2022.
  • Over the past 5 years, Ani Pharmaceuticals' Non-Current Debt (Quarter) stood at $286.5 million in 2021, then fell by 0.3% to $285.7 million in 2022, then dropped by 0.3% to $284.8 million in 2023, then increased by 8.53% to $309.1 million in 2024, then decreased by 3.7% to $297.7 million in 2025.
  • Its Non-Current Debt was $297.7 million in Q3 2025, compared to $301.5 million in Q2 2025 and $305.3 million in Q1 2025.